Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report Q1, 2022

First quarter 2022 · Net sales amounted to MSEK 24.1 (7.5) · EBITDA amounted to MSEK -1.8 (-2.7) · EBIT* amounted to MSEK -26.9 (-22.7*)  · EBT amounted to MSEK -28.3 (-27.4) · Earnings per share before dilutions amounted to -0.08 (-0.12) Significant events during the reporting period · Ur & Penn chooses Ampilio, subsidiary of SpectrumOne, as partner to execute EU expansion via Amazon · Qbim, subsidiary of SpectrumOne, has qualified for becoming one of the preferred suppliers of Business Intelligence services to Region Värmland · BellPal chooses Ampilio as

Hannover Medical School expands its treatment arsenal and includes Integrum’s OPRA[TM] Implant System

Mölndal, Sweden, May 2[nd], 2022 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that Hannover Medical School has expanded its treatment arsenal and implemented OPRA[TM] Implant System in clinical use. The first surgeries with the technique have successfully been completed and the hospital will continue to offer the treatment to suitable patients with above-knee, arm, and digit amputations.Hannover Medical School is the hospital that has tradition with osseointegration in Germany. In October 2022 the new chief of the trauma department - Prof. Stephan Sehmisch-

Cereno Scientific nominates drug candidate CS014 in HDACi Program for continued development in cardiovascular disease

Cereno Scientific (XSAT: CRNO B) today announced the nomination of drug candidate CS014 for continued development in the preclinical HDACi (histone deacetylase inhibitor) Program. After completing the first half of the preclinical development program, CS014 was nominated after demonstrating highest potential in cardiovascular disease among a set of similar molecules. CS014 is being developed with the aim to provide a better treatment for patients with cardiovascular disease.“It is great to announce that we have made good advancement in the preclinical HDACi Program, resulting in the

Trading in NeoDynamics shares on Nasdaq First North starts today

Shares in the MedTech company NeoDynamics AB (publ) starts trading on Nasdaq First North Growth Market in Stockholm today. “Trading on Nasdaq strengthens our credibility in the US market, where we intend to introduce our biopsy system NeoNavia and also look for partners”, says NeoDynamic's CEO Anna Eriksrud. The listing ceremony can be watched on the following link: https://vimeo.com/event/1411317/6f4ff7bb35 Shareholders in NeoDynamics will not have to take any action in connection with the list change. The shares will trade under the same ticker, NEOD and ISIN code SE SE0011563410.

Scandi Standard – First quarter presentation

Scandi Standard will publish its report for the first quarter of 2022 on Wednesday, 4 May 2022, at 07.30 CET.  Conference call at 08.3o CET The Company will host a conference call for the financial community at 08.30 CET on the same day. The conference call will be hosted by Jonas Tunestål, CEO, and Julia Lagerqvist, CFO.   Dial-in numbers: United Kingdom 0800 640 6441 United Kingdom (Local) 020 3936 2999 Sweden (Local): 010 884 80 16 USA (local): 1 646 664 1960 All other locations +44 20 3936 2999   Participant Access Code:  375363   The

Realheart has been granted two more US patents

Press release 2 May, 2022 Realheart is developing the world's first artificial four-chamber heart. The company has now been granted a new US patent that protects the entire principle behind it through 2037. In addition, the company has obtained similar protection for its sternal prosthesis, a separate product designed to facilitate chest surgery.''This is extremely valuable as it provides a strong two-layer protection for our artificial heart in one of the world's most important markets and further strengthens our overall patent portfolio'' said Realheart CEO Ina Laura Perkins. In

CapMan Growth to accelerate growth of multi-cloud company Cloud2

CapMan Growth Press ReleaseMay 2[nd] 2022 at 9:30 AM EEST CapMan Growth to accelerate growth of multi-cloud company Cloud2 CapMan Growth invests in and becomes minority owner of multi-cloud service provider Cloud2, a company focused on developing and managing cloud environments. The ongoing cloud transformation trend has accelerated the growth of Helsinki-based Cloud2, which holds unique competencies in Amazon AWS, Microsoft Azure and Google Cloud, cloud environments. Multi-cloud expertise has spearheaded Cloud2’s offering since the beginning. Most larger companies

Business update for BICO Group AB (publ)

BICO hereby provides an extraordinary update on the company's financial and operational development. The information precedes the interim report for the period January-March 2022, which will be published on May 18, 2022.The business update provides a preliminary announcement of the company's financial performance as of March 31, 2022, and indicates that BICO delivered results that are in line with and exceed the company's financial targets. The financial targets, which have previously been communicated, state that the annual organic growth should be above 35 percent, and that the company

Qt Group Plc - Managers' Transactions – Turunen

Qt Group Plc, Stock exchange release, May 2, 2022 at 9:30 am EESTQt Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tuukka Turunen Position: Other senior manager Issuer: Qt Group Plc LEI: 743700GO2XU2ZYYDKW67 Notification type: INITIAL NOTIFICATION Reference number: 13737/4/4 ____________________________________________ Transaction date: 2022-04-29 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000198031 Nature of the transaction: ACQUISITION

Alfa Laval acquires patented technology to strengthen its position in carbon-neutral fuel processing

Alfa Laval has acquired patented technology from the Danish company RenCat to reform hydrogen from ammonia. This technology, in combination with Alfa Laval’s heat transfer expertise, will increase the business opportunities within the growing market for hydrogen processing, facilitating the use of renewable fuels in the future.  The signing and closing date was 29 April, 2022.There is growing demand for cleaner fuel alternatives to meet carbon reduction targets. Ammonia is projected to be one of the clean energy bearers both in the shipping industry, as well as for land-based applications.

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 29th April 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,788,174 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Interim Report Q1 – January – March, 2022 Redsense Medical AB (publ)

January – March 2022 · Net sales amounted to kSEK 3,127 (685), an increase by 356 percent. · Operating loss, EBIT amounted to kSEK 2,076 (3,150). · Result after tax amounted to kSEK -1,549 (-1,489). · Earnings per share was SEK -0.11(-0.11) before and after dilution. Significant events during the period · On March 14, Redsense Medical successfully participated in a virtual briefing about venous needle dislodgement (VND) for US congress together with multiple professional renal organizations and advocacy associations. · On March 15, Redsense Medical announced that

Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.

May 2, 2022: Biosergen today announced that it is preparing a Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus. Mucormycosis is a difficult to treat fungal infection with high mortality.As novel fungicidal polyene antifungal product BSG005 is well positioned to provide a broad single product treatment alternative for life threatening, difficult to treat, resistant, invasive fungal infections. Different to other polyene products, such as Amphotericin B or Ambisome, BSG005 is without any signs of nephrotoxicity. To support this unique product profile,

Caverion acquires the business of Kaldt og Varmt AS, a heating and cooling specialist in Norway

Caverion Corporation Investor news 2 May 2022 at 9.15 a.m. EESTCaverion acquires the business of Kaldt og Varmt AS, a heating and cooling specialist in Norway Caverion has closed an agreement to acquire the business of Kaldt og Varmt AS (“Kaldt og Varmt”) in Norway. Kaldt og Varmt is a heating and cooling specialist based in Askim, Norway. The acquisition complements Caverion’s service offering in the region. Kaldt og Varmt operates in the Oslo area and its eastern surroundings. Since its establishment in 2016, the company has grown to be a solid player in the industry that also

XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022

XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].The abstract, titled Autologous NK Cells as Consolidation After Front-Line Stem Cell Transplantation in Multiple Myeloma: A Long-Term Follow-Up, will be presented by the first author Johan Lund at a poster session on Friday, June 10, 16:30 - 17:45 CEST. The other authors

Invitation to Embracer Group’s presentation on its acquisition of Eidos, Crystal Dynamics and Square Enix Montréal at 09.00 (CEST)

Embracer Group hereby invites you to a presentation on today’s press release and announcement of the acquisition of Eidos, Crystal Dynamics and Square Enix Montréal amongst other assets.The presentation will be held in English by CEO Lars Wingefors together with Phil Rogers, CEO Square Enix America and Europe, Scot Amos, Studio Head Crystal Dynamics, David Anfossi, Studio Head Eidos Montréal and Patrick Naud, Studio Head Square Enix Montréal. A Q&A session will follow the presentation. Date:           May 2, 2022 Time:          09:00 (CEST) Online:        Welcome to participate

Managers’ transactions – Koskinen

Nordea Bank AbpStock exchange release – Managers’ transactions2 May 2022 at 09.00 EET Transaction notification under Article 19 of the EU Market Abuse Regulation Person subject to the notification requirementName: KOSKINEN, JUSSIPosition: OTHER SENIOR MANAGERIssuer: Nordea Bank AbpLEI: 529900ODI3047E2LIV03 Notification type: INITIAL NOTIFICATIONReference number: 13750/11/8 Transaction date: 2022-04-29Venue: XHELInstrument type: SHAREISIN: FI4000297767Nature of the transaction: Acquisition Transaction details(1): Volume: 1,000 Unit price: 9.45300 EUR

Managers’ transactions – Vang-Jensen

Nordea Bank AbpStock exchange release – Managers’ transactions2 May 2022 at 09.00 EET Transaction notification under Article 19 of the EU Market Abuse Regulation Person subject to the notification requirementName: VANG-JENSEN, FRANKPosition: CHIEF EXECUTIVE OFFICERIssuer: Nordea Bank AbpLEI: 529900ODI3047E2LIV03 Notification type: INITIAL NOTIFICATIONReference number: 13719/12/10 Transaction date: 2022-04-29Venue: XCSEInstrument type: SHAREISIN: FI4000297767Nature of the transaction: Acquisition Transaction details(1): Volume: 13  Unit price: 71.62000

AcadeMedia publishes the Nomination Committee for the AGM 2022

In accordance with the principles adopted by the Annual General Meeting 2020, the nomination committee shall comprise one representative for each of the three largest shareholders based on ownership of the company as per the end of the financial year’s third quarter. The chairman of the board shall be a co-opted member (Sw. adjungerad). The Nomination Committee for the Annual General Meeting on 30 November 2022 consists of:Rune Andersson, Mellby GårdMats J. Andersson, Nordea FonderJoachim Spetz, Swedbank Robur Fonder For more informationhttps://academedia.se/en/investors/

One of the Nordic region’s leading financial software companies presents the best financial result since new ownership

Vitec Aloc, one of the Nordic region’s leading companies within capital market software, is ready with its financial statement for 2021. Profits are the highest since the new strategic ownership, and the bottom line reflects increasing growth. The main reason for this is the implementation of a new business model and the continuous work on professionalisation and focus on quality.The Danish provider of investment management solutions to some of the largest banks, asset managers, family offices and pension and insurance companies in Scandinavia, Vitec Aloc, can today present pre-tax profits

Concentric AB announces a restatement of segmental reporting

Following the acquisition of EMP and an internal organisation and reporting review, the Board of Directors has decided Concentric AB will report by technology segments, namely Engines and Hydraulics, rather than geographical regions, which is consistent with both how the business will be managed and reported internally in the future. The Engine division will include all Concentric, Licos and EMP branded engine products, including royalties and net income from our joint venture, Alfdex. The Hydraulics division will include Concentric and Allied branded hydraulic products. This change is

Invitation to the presentation of SLP’s results for January–March 2022

Swedish Logistic Property AB (“SLP”) will publish its interim report for the first quarter of 2022 on Wednesday, 4 May 2022, at 08:45 a.m. CEST. The interim report will be presented via a recorded audiocast at 10:00 a.m. on the same day.Peter Strand, CEO, and Tommy Åstrand, CFO, will present the results and operations. The presentation material (images+audio) will be available at: https://slproperty.se/en/ir/reports-and-presentations/ and https://tv.streamfabriken.com/slp-q1-rapport-2022 The presentation will be held in Swedish. Questions can be submitted in writing via email to info@

STENOCARE is ready to start delivery of their THC oil products to Danish patients

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This is a follow-up from the press release 07.01.2022, that announced STENOCARE had received product approval from the Danish Medicines Agency to have a medical cannabis oil product accepted into the Danish Pilot Programme.Waiting time is over and sales can begin: STENOCARE has now completed the import of the new medical cannabis oil product into Denmark. The product is named THC Olie STENOCARE and is available in 30 mL bottles with a strength of 30 mg/mL THC and <0.1 mg/mL CBD. Dosing is delivered via an oral

Swedish start-up AI Medical Technology initiates clinical study in primary care facilities to validate Dermalyser – an AI-driven support tool for diagnosing malignant melanoma

Stockholm, Sweden, May 2, 2022. On the first day of this year’s Skin Cancer Awareness Month, Swedish Artificial Technology start-up AI Medical Technologies announces the start of a clinical trial at 30 Swedish primary care facilities with Dermalyser, a diagnostic decision support system empowered with advanced artificial intelligence (AI). The study is a prospective, pivotal confirmatory multi-centre, non-interventional clinical investigation with the following aims: 1. Evaluate the clinical safety, performance and benefit of Dermalyser in patients with cutaneous lesions where malignant

There are no items matching the current filter
There are no more items matching the current filter
Back to top